In an FDA reported letter Biogen and Elan issued concerns about the development of significant liver damage as a result of beginning Tysabri therapy.
Your email is never published nor shared. Required fields are marked *
You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
Tysabri Adds Liver Injury Watch
In an FDA reported letter Biogen and Elan issued concerns about the development of significant liver damage as a result of beginning Tysabri therapy.